AR022318A1 - Utilizacion de imidazo[1,5-a]-pirido [3,2-e]-pirazinonas como inhibidores de la fosfodiesterasa 5 para tratar la disfuncion erectil, como inhibidoresduales de la fosfodiesterasa 3 y de la fosfodiesterasa 5 para tratar la insuficiencia cardiaca, hipertonia pulmonar y angiopatias, que estan acompanada - Google Patents

Utilizacion de imidazo[1,5-a]-pirido [3,2-e]-pirazinonas como inhibidores de la fosfodiesterasa 5 para tratar la disfuncion erectil, como inhibidoresduales de la fosfodiesterasa 3 y de la fosfodiesterasa 5 para tratar la insuficiencia cardiaca, hipertonia pulmonar y angiopatias, que estan acompanada

Info

Publication number
AR022318A1
AR022318A1 ARP000100246A ARP000100246A AR022318A1 AR 022318 A1 AR022318 A1 AR 022318A1 AR P000100246 A ARP000100246 A AR P000100246A AR P000100246 A ARP000100246 A AR P000100246A AR 022318 A1 AR022318 A1 AR 022318A1
Authority
AR
Argentina
Prior art keywords
14aryl
alkyl
several times
inhibitors
phosphodiesterase
Prior art date
Application number
ARP000100246A
Other languages
English (en)
Spanish (es)
Original Assignee
Dresden Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/de
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/de
Application filed by Dresden Arzneimittel filed Critical Dresden Arzneimittel
Publication of AR022318A1 publication Critical patent/AR022318A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP000100246A 1999-01-20 2000-01-19 Utilizacion de imidazo[1,5-a]-pirido [3,2-e]-pirazinonas como inhibidores de la fosfodiesterasa 5 para tratar la disfuncion erectil, como inhibidoresduales de la fosfodiesterasa 3 y de la fosfodiesterasa 5 para tratar la insuficiencia cardiaca, hipertonia pulmonar y angiopatias, que estan acompanada AR022318A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999102082 DE19902082A1 (de) 1999-01-20 1999-01-20 Verwendung von Imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erectiler Dysfunktion und Verfahren zu deren Herstellung
DE1999161302 DE19961302A1 (de) 1999-12-18 1999-12-18 Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen

Publications (1)

Publication Number Publication Date
AR022318A1 true AR022318A1 (es) 2002-09-04

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100246A AR022318A1 (es) 1999-01-20 2000-01-19 Utilizacion de imidazo[1,5-a]-pirido [3,2-e]-pirazinonas como inhibidores de la fosfodiesterasa 5 para tratar la disfuncion erectil, como inhibidoresduales de la fosfodiesterasa 3 y de la fosfodiesterasa 5 para tratar la insuficiencia cardiaca, hipertonia pulmonar y angiopatias, que estan acompanada

Country Status (23)

Country Link
EP (1) EP1144410A2 (id)
JP (1) JP2002535330A (id)
KR (1) KR20010101603A (id)
CN (1) CN1344268A (id)
AR (1) AR022318A1 (id)
AU (1) AU2291200A (id)
BG (1) BG105714A (id)
BR (1) BR0007613A (id)
CA (1) CA2296224A1 (id)
CO (1) CO5190700A1 (id)
CZ (1) CZ20012627A3 (id)
EA (1) EA200100792A1 (id)
EE (1) EE200100377A (id)
HU (1) HUP0105132A3 (id)
ID (1) ID29790A (id)
IL (1) IL144156A0 (id)
IS (1) IS5987A (id)
LT (1) LT2001078A (id)
LV (1) LV12793B (id)
NO (1) NO20013334L (id)
SK (1) SK10322001A3 (id)
TR (1) TR200102121T2 (id)
WO (1) WO2000043392A2 (id)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
WO2003051346A2 (en) * 2001-12-17 2003-06-26 Altana Pharma Ag Use of selective pde5 inhibitors for treating partial and global respiratory failure
FR2835741B1 (fr) * 2002-02-12 2006-05-05 Oreal Nouveaux coupleurs 6-alcoxy-2,3-diaminopyridine utiles pour la teinture des fibres keratiniques
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
AU2005277384B2 (en) * 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
EP2103613B1 (en) * 2006-12-13 2016-02-17 ASKA Pharmaceutical Co., Ltd. Quinoxaline derivative
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
AU2008329775A1 (en) 2007-11-30 2009-06-04 Biotie Therapies Gmbh Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
CA2886885C (en) 2011-10-10 2019-07-16 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone
US9434733B2 (en) 2012-01-26 2016-09-06 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
JP5842640B2 (ja) * 2012-01-31 2016-01-13 株式会社東洋新薬 ホスホジエステラーゼ３阻害剤
US9938284B2 (en) 2014-08-07 2018-04-10 Intra-Cellular Therapies, Inc. Organic compounds
US10005789B2 (en) 2014-08-07 2018-06-26 Intra-Cellular Therapies, Inc. Organic compounds
SI3865484T1 (sl) 2015-07-07 2024-05-31 H. Lundbeck A/S Zaviralec pde9 z imidazo pirazinonsko hrbtenico za zdravljenje perifernih bolezni
JP2021526134A (ja) 2018-05-25 2021-09-30 イマラ インク． ６−［（３Ｓ，４Ｓ）−４−メチル−ｌ−（ピリミジン−２−イルメチル）ピロリジン−３−イル］−３−テトラヒドロピラン−４−イル−７Ｈ−イミダゾ［ｌ，５−Ａ］ピラジン−８−オンの一水和物および結晶形態

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
CO5190700A1 (es) 2002-08-29
WO2000043392A2 (de) 2000-07-27
JP2002535330A (ja) 2002-10-22
IL144156A0 (en) 2002-05-23
IS5987A (is) 2001-06-29
KR20010101603A (ko) 2001-11-14
NO20013334D0 (no) 2001-07-05
LT2001078A (en) 2002-08-26
NO20013334L (no) 2001-07-05
EE200100377A (et) 2002-10-15
SK10322001A3 (sk) 2002-07-02
CZ20012627A3 (cs) 2002-01-16
EP1144410A2 (de) 2001-10-17
ID29790A (id) 2001-10-11
HUP0105132A2 (hu) 2002-05-29
TR200102121T2 (tr) 2002-01-21
CA2296224A1 (en) 2000-07-20
AU2291200A (en) 2000-08-07
CN1344268A (zh) 2002-04-10
LV12793B (lv) 2002-05-20
LV12793A (lv) 2002-02-20
EA200100792A1 (ru) 2002-10-31
HUP0105132A3 (en) 2002-12-28
BG105714A (en) 2002-02-28
BR0007613A (pt) 2001-10-30
WO2000043392A3 (de) 2000-09-28

Similar Documents

Publication Publication Date Title
AR022318A1 (es) Utilizacion de imidazo[1,5-a]-pirido [3,2-e]-pirazinonas como inhibidores de la fosfodiesterasa 5 para tratar la disfuncion erectil, como inhibidoresduales de la fosfodiesterasa 3 y de la fosfodiesterasa 5 para tratar la insuficiencia cardiaca, hipertonia pulmonar y angiopatias, que estan acompanada
GT200000168A (es) Compuestos farmaceuticamente activos.
GT200000069A (es) Derivados heterociclicos utiles como agentes anticancerosos.
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
MX9307940A (es) Nuevos derivados de la imidazopiridina, proceso para su preparacion y formulaciones farmaceuticas que los incluyen
PE20070018A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PE20040897A1 (es) 8-[3-amino-piperidin-1-il]-xantinas y su preparacion como medicamentos
ATE439168T1 (de) Haarfärbemittel enthaltend unlösliche derivate und verfahren
ECSP045379A (es) Derivados de [1,4]diazepino[6,7,1-ij]quinolina como agentes antipsicóticos y contra la obesidad
SV2003001173A (es) 1-alquil o 1-cicloalquil-triazolo [4,3-a] quinazolin-5- onas como inhibidoras de fosfodiesterasa
CL2007000916A1 (es) Uso de alcaftadina y de acido 6,11-dihidro-11-(1-metil-4-piperidiniliden)-5h-imidazo[2,1-b][3]benzazepin-3-carboxilico, sales, n-oxidos, solvatos e hidratos para tratar sintomas de alergia ocular, inflamacion ocular y sintomas nasales de alergia ocular; composiciones oftalmicas que los comprenden; su uso y kit farmaceutico.
BR0006380A (pt) Derivados de 2-aminoalquil-1,4-diamino-benzeno e agentes de tingimento contendo estes compostos
PE20030208A1 (es) Derivados de indirubina que contienen azufre, su preparacion y uso
PE20030664A1 (es) DERIVADOS DE TRIAZOLO [4,3-a]PIRIDO[2,3-d]PIRIMIDIN-5-ONA, COMPOSICIONES QUE LOS CONTIENEN, METODO DE PREPARACION Y USO
ES2101858T3 (es) Derivados de geneserina como inhibidores de colinesterasa.
TR199902495T2 (xx) Bile�imler.
BRPI0507616A (pt) compostos para tingimento de queratina, composições para tingimento de queratina compreendendo esses compostos e uso de tais composições
ES2175386T3 (es) Derivados de 2,3-benzodiazepina y su utilizacion como inhibidores de receptores de ampa.
Xia et al. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido [1, 2-e] purin-4 (3H)-one derivatives
CA2445625A1 (en) Pyrazino'1',2':1,6!pyrido'3,4-b!indole1,4-dione derivatives
ES2059931T3 (es) Procedimiento para el tratamiento de la hipertrofia e hiperplasia cardiaca asi como vascular.
MXPA03008250A (es) Nuevos derivados de diaminopirazol y colorantes que contienen estos compuestos.
TR200103237T2 (tr) İmidazodiazepin türevi
PE20061443A1 (es) DERIVADOS DEL ACIDO 6,7-DIHIDRO-5H-IMIDAZO[1,2-a]IMIDAZOL-3-SULFONICO
AR015518A1 (es) Uso de derivados de tiadiazolo piridina para la produccion de un medicamento para el tratamiento de enfermedades que se modulan mediante la inhibicion delas fosfodiesterase(s)